Climate-related Supply Chain Risks: How Do Companies Measure Up?

A recent analysis by the US Government Accountability Office (GAO) examined how companies are complying with US Securities and Exchange Commission (SEC) disclosure requirements as they apply to climate-change matters. So how are companies measuring up?

Disruptions to global supply chains, such as those caused by natural disasters, can hurt economic growth and productivity around the world. These events may pose risks to private-sector companies by, for example, disrupting supply chains. Under federal securities laws, certain companies are required to disclose specified information in annual filings with the SEC, and the SEC issued guidance in 2010 to assist companies in satisfying these disclosure requirements as they apply to climate-change matters. DCAT Value Chain Insights (VCI) examines how companies fared.

Setting the stage
SEC's 2010 guidance was published by the SEC to provide guidance to companies on how existing disclosure requirements apply to climate-change matters. The 2010 guidance describes some climate-related impacts that companies may face, including risks to their supply chains, and under what circumstances these impacts could trigger disclosure requirements. Companies may disclose climate-related supply chain risks under four broad categories of climate-related topics that the SEC identified in its 2010 guidance as some of the ways companies may be impacted. These categories are (1) impacts of legislation and regulation related to climate change; (2) impact of international accords; (3) indirect consequences of regulation or business trends, such as decreased demand for goods that produce significant greenhouse gas emissions; and physical impacts, such as changes in water availability. In addition to SEC disclosure, companies may disclose climate-related risks through other channels, such as nongovernmental organizations, company websites, and foreign entities.

The GAO report examines: (1) the types of climate-related supply chain risks companies are disclosing in their SEC filings and other channels through which companies may disclose climate-related supply chain risks; (2) how SEC considers climate-related supply chain risks when monitoring and enforcing compliance with disclosure requirements; and (3) what actions, if any, SEC has taken to identify climate-related supply chain risk information that investors may need. The GAO conducted a review and audit from March 2015 to January 2016 on 973 company filings.

Examples of climate-change risks
Table I outlines categories of climate-change risks identified by the SEC and examples of how they could trigger disclosure rules.

Table I: Categories of Climate Change Risks Identified by the Securities and Exchange Commission (SEC) and Examples of How They Could Trigger Disclosure Rules
Category of climate-change risk Definition Examples
Legislation and regulation Pending or existing regulations or legislation related to climate change at all levels of government Companies could face costs from improving facilities and equipment to reduce emissions in order to comply with regulatory limits. They could also face costs to purchase, or profit from the sale of, allowances or credits under a “cap and trade” system.
International accords Treaties or international accords relating to climate change The European Union Emissions Trading System could have a material impact on a company's business, which could potentially be the same as the impact from US climate change legislation and regulation.
Indirect consequences of regulation or business trends New opportunities or risks created by legal, technological, political, or scientific developments related to climate change. Companies may face decreased demand for goods that produce significant greenhouse gas emissions. They may also face reputational risk, with potential adverse consequences to business operations or financial condition, from the public's perception of publicly available data relating to their greenhouse gas emissions.
Physical impacts Significant physical effects of climate change that could affect a company's operations and financial results. Physical effects could include effects on severity of storms, sea levels, and water availability. Severe weather could cause property damage and disruptions to operations for companies with operations concentrated on coastlines. It could also cause indirect financial and operational impacts from disrupting the operations of major customers or suppliers.

Source: US Government Accountability Office, “Supply Chain Risks: SEC's Plans to Determine If Additional Action Is Needed on Climate-Related Disclosure Have Evolved,” (Washington, DC. January 2016).

Review process and future considerations
As part of its review process, the SEC considers climate-related supply chain risks as it considers the totality of information that companies are required to disclose in its routine monitoring processes and it may consider allegations of inadequate or fraudulent disclosures as part of its enforcement process.The SEC, through its Division of Corporation Finance, seeks to ensure that companies provide required information in order for investors to make informed investment decisions. According to SEC documents, during the Division of Corporation Finance's review, the staff check to see if companies are meeting their disclosure requirements and seeks to enhance companies' compliance with disclosure requirements.

To accomplish this, the Division of Corporation Finance conducts the following three main types of reviews:

Initial reviews. A company's initial registration statement is reviewed to evaluate compliance with applicable disclosure and accounting requirements.

Periodic filing reviews. In addition to the initial review, according to the SEC staff, each reporting company's financial statements are examined at least once every three years and many companies are reviewed more frequently; many companies' nonfinancial disclosures are also reviewed.

Selective reviews. Transactional filings, such as documents that companies file with SEC when they engage in public offerings and other actions, are selectively reviewed at the discretion of the Division of Corporation Finance. The Division of Corporation Finance performs these reviews through offices that focus on specific industries. According to the SEC staff, reviewers spend many years reviewing the same industries and, as a result, develop industry-specific expertise with regard to expected disclosure items in a particular industry, including climate-related disclosure. A review team from the appropriate industry office is assigned to each filing that is selected for review. At times, an engineer may be involved in a review.

The GAO report notes that some stakeholder groups interested in climate-related disclosure issues have requested that SEC take additional actions to increase climate-related information disclosed in companies' filings. The GAO report says that the SEC has no plans to specifically determine if additional actions related to disclosure of climate-related risks are necessary or appropriate in the public interest or for the protection of investors, but that other potential and ongoing efforts by the agency could address climate-change disclosure.

Specifically, the Office of the Investor Advocate is tasked with proposing to SEC, to the extent practicable, changes to its regulations or orders that may be appropriate to mitigate identified problems and promote the interests of investors, among other things. According to the Investor Advocate, climate-related risk disclosure is an issue that his office—including its Ombudsman—could consider reviewing, though it has no formal plans to do so. Additionally, SEC's disclosure effectiveness project, which began in December 2013, could address the subject of climate-related disclosure. The SEC is reviewing the current disclosure requirements to evaluate it might refine them to more effectively provide investors with the information they need to make informed decisions. For example, if the SEC identified gaps in disclosure or opportunities to increase the transparency of information, the SEC could potentially recommend new disclosure requirements. As of October 2015, the project is in its initial phase focusing on business and financial disclosure requirements, and SEC staff have not recommended changes to the SEC. Although the disclosure effectiveness project is broad and does not specifically focus on climate-related disclosure, or the 2010 guidance, the project provides investors, companies, and other stakeholders with opportunities to provide comments to SEC on any disclosure topic, including disclosure of climate-related risks to supply chains.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

The CDMO/CMO Report: Cell and Gene Therapies

Although a niche market, cell and gene therapy development and manufacturing continues to be an active area of investment by CDMOs/CMOs. Facing limited industry capacity, both pure-play CDMOs and bio/pharma companies with CDMO services continue to expand. A roundup of the latest expansions.

Pharma Innovation: AI in Drug Manufacturing

What is the potential of artificial intelligence (AI) in pharmaceutical manufacturing and what regulatory considerations come into play, including between CDMOs/CMOs and sponsor companies? The FDA has issued a discussion paper to highlight key issues and is seeking input from the industry.

Pharma Industry Outlook: What Lies Ahead?

With 2023 well underway, the crucial question is: how will the bio/pharmaceutical industry perform in 2023 and the near term? The DCAT Week program, Pharma Industry Outlook, will provide key market data and trends. Plus, a pharma financial outlook and analysis of M&A, partnering deals, and private and public financing into Emerging Pharma. 

ROI in Pharma R&D Falls in Post-Pandemic Market

A recent analysis by the management consultancy firm, Deloitte, shows that the bio/pharma industry’s return on investment (ROI) in R&D has fallen in the post-pandemic market. Projected ROI in pharma R&D in 2022 fell to 1.2%, the lowest ROI observed in the 13 years since the firm has conducted the study.